Chronic Lymphocytic Leukemia with Jan A. Burger, MD, PhD
Case 1:A Fit Elderly Patient with Newly-Diagnosed Chronic Lymphocytic Leukemia.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More